Primary progressive multiple sclerosis

Disease ID:1235
Name:Primary progressive multiple sclerosis
Associated with:0 target
1 immuno-relevant ligand
Synonyms
PPMS | Primary-progressive MS
Description
This type of multiple sclerosis is characterized by steady worsening of neurologic functioning with no presentation of distinct relapses or periods of remission.
Database Links
Disease Ontology: DOID:0050784

Targets

No target related data available for Primary progressive multiple sclerosis

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
ocrelizumab
Immuno Disease Comments: Ocrelizumab is approved to treat PPMS.
Clinical Use: The US FDA had granted breakthrough therapy designation for ocrelizumab for the treatment of primary progressive multiple sclerosis which converted to full FDA approval for the treatment of relapsing and primary progressive types of multiple sclerosis in March 2017. Phase III clinical trials eg NCT01194570 and NCT01247324 were used to evaluate ocrelizumab clinical potential.

Development of this antibody as a treatment for other inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, and B-cell malignancies has been suspended [1-2]. | View clinical data
Bioactivity Comments: Ocrelizumab depletes CD20+ B cells in the blood and lymphoid tissues of cynomolgus monkeys (Macaca fascicularis) [3]. B cell numbers recover to normal levels after one or two treatments [3]. Affinity data for clone 2H7.v16 is presented below. Clone 2H7.v31 exhibited 20-fold higher antibody-dependent cell-mediated cytotoxicity (ADCC) than the approved anti-CD20 monoclonal . | View biological activity

References

Show »

1. Hutas G. (2008) Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs, 9 (11): 1206-15. [PMID:18951300]

2. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther, 9 (7): 889-95. [PMID:19463076]

3. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W et al.. (2005) Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother., 28 (3): 212-9. [PMID:15838377]